advertisement

HongKong Nasopharyngeal

50 %
50 %
advertisement
Information about HongKong Nasopharyngeal
Education

Published on January 21, 2008

Author: Monica

Source: authorstream.com

advertisement

Slide1:  For demonstration of interpreting a strong positive interaction see slides 25-30. NPC-9902 Trial on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Cancer:  NPC-9902 Trial on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Cancer Anne W. M. Lee for Hong Kong Nasopharyngeal Cancer Study Group Estimation on Sample & Eligible Patients:  Estimation on Sample & Eligible Patients Incidence in Hong Kong: CT-staged patients NPC-9902: Eligibility Criteria:  NPC-9902: Eligibility Criteria Non-keratinizing / Undifferentiated type T3-4 N0-1 M0 (UICC 5th) Staging Ix: CT / MR X-ray / CT thorax + metastatic work-up Eligibility Criteria :  Eligibility Criteria Slide6:  CF CF+C Stratification by center, N-stage, T-stage Randomization (equal proportion) AF AF+C CF = conventional fractionation; AF = accelerated fractionation; +C = plus chemotherapy RT: Same for all Arms:  RT: Same for all Arms RT: Fractionation:  RT: Fractionation Fractionation dose: 2 Gy/ Fr Treatment in CRT Arm:  Treatment in CRT Arm Chemotherapy (IGS regimen)   Concurrent Adjuvant P 80 + 5FU 1000 x 4d (q4 wk x 3 cycles) Statistical Consideration:  Statistical Consideration Target accrual = 464 patients Hypothesis Improve Failure-Free Survival (FFS) [Time to failure (any site)] from 45% to 55% (5-year) (alpha = 0.05, power = 90%) Other End Points:  Other End Points Progression-Free Survival (PFS) [Time to first failure or death (any cause)] Overall Survival Participating Centers:  Participating Centers Accrual Rate:  Accrual Rate July 1999 – April 2004: 189 patients Slide14:  Premature Termination due to Slow Accrual Recommendation by Data Monitoring Committee Results:  Results Period: Jul 1999 – Apr 2004 Total No. randomized: 189 pt. Regular follow-up: 97% Median follow-up: 2.9 (0.1 – 5.5) yr Patient Characteristics:  Patient Characteristics Tumor Staging:  Tumor Staging Radiotherapy:  Radiotherapy Comparison of Prognostic Factors:  Comparison of Prognostic Factors RT vs CRT All balanced CF vs AF All balanced Arm Balanced except AF Arm vs other Arms: Male: 90% vs 70% (p = 0.046) PS 2: 4% vs 0% Non-Chinese: 4% vs 0% Major Violation of Protocol:  Major Violation of Protocol Compliance to Chemotherapy:  Compliance to Chemotherapy AF+C 84% 73% Concurrent cycles: > 2 Adjuvant cycles: > 3 CF+C 92% 64% Acute Toxicity (Grade >3):  Acute Toxicity (Grade >3) Chemotherapy Toxicity in CRT Arm:  Chemotherapy Toxicity in CRT Arm Overall Acute Toxicity (Grade >3):  Overall Acute Toxicity (Grade >3) Overall Acute Toxicity (Grade >3):  Overall Acute Toxicity (Grade >3) Failure-Free Survival (3-year):  Failure-Free Survival (3-year) RT vs CRT 66% vs 83% (p = 0.05) AF vs AF 72% vs 77% (p = 0. 31) (Event: any failure) AF+C CF AF AF+C Year Probability P=0.01 Failure-Free Survival (3-year):  Failure-Free Survival (3-year) CF This represents a significant interaction effect. What does it mean? Effects of CRT and AF are non-additive: Effect of CRT is enhanced in presence of AF and Effect of AF is enhanced in presence of CRT. Is it real? Is CRT useless without AF? Is AF useless without CRT? Slide28:  Hazard Ratio = .11 = 1/9  Nine-fold decrease in failure with AF + CRT together rather than separately. But the decrease is a product of three effects: RT + AF CRT + CF RT + CF ------------------------------------------------ CRT + AF CRT alone, HR  1.1 AF alone, HR  1.4 CRT + AF, HR  6 1.1  1.4  6 = 9, the total effect Slide29:  That is, the benefit due to CRT + AF being delivered in tandem vs. separately is due to: The apparent disadvantage of CRT + CF over RT + CF (1.1 increase); The apparent disadvantage of RT + AF over RT + CF (1.4 increase); and The advantage of CRT + AF over RT + CF (six-fold reduction): 1.1  1.4  6 = 9, the total interaction effect. A clinically important question::  A clinically important question: Suppose we don’t believe the first two effects – we don’t believe that acceleration or adding chemotherapy can cause failures, and fix their hazard ratios at 1.0: What is the significance of the “restricted interaction effect”, the hazard ratio of 6? Answer: p = ????. Modest evidence that AF and CRT do seem to work better together. Locoregional Failure-Free Rate (3-year):  Locoregional Failure-Free Rate (3-year) RT vs CRT 81% vs 87% (p = 0.41) AF vs AF 83% vs 85% (p = 0. 63) Probability Year P=0.14 AF+C CF CF+C AF Distant Failure-Free Rate (3-year):  Distant Failure-Free Rate (3-year) RT vs CRT 79% vs 93% (p = 0.06) AF vs AF 85% vs 86% (p = 0. 55) Year Probability AF+C CF CF+C AF P=0.10 Disease Status at Last Assessment:  CF+C 69 6 8 12 2 2 2 CF 71 5 7 14 - - 2 Disease Status at Last Assessment AF 67 6 4 19 - 2 2 AF+C 89 - - 5 - 7 - Overall Survival :  Overall Survival RT vs CRT 77% vs 87% (p = 0.41) AF vs AF 85% vs 79% (p = 0.73) Year Probability AF+C CF AF CF+C P=0.56 Progression-Free Survival :  Progression-Free Survival (Event: failure or death) RT vs CRT 65% vs 80% (p = 0.19) AF vs AF 71% vs 74% (p = 0.34) Year Probability AF+C CF+C CF AF P=0.09 Late Toxicity (Grade >3):  Late Toxicity (Grade >3) RT vs CRT 19% vs 33% (p = 0.08) AF vs AF 23% vs 28% (p = 0.32) Year Probability AF+C CF+C AF CF P=0.24 Late Toxicity (Grade >3):  Late Toxicity (Grade >3) Subset Analyses – Absolute Gain:  Subset Analyses – Absolute Gain

Add a comment

Related presentations

Related pages

Hong Kong Nasopharyngeal Cancer Symposium 2014 » Cheung ...

Dear Colleagues, It is our pleasure to announce that the Hong Kong Nasopharyngeal Cancer Symposium will be held in Hong Kong, August 23 – 24, 2014.
Read more

Department of Clinical Oncology - Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is a major public health problem in Hong Kong with an annual incidence of 15.4/100,000.
Read more

Nasopharyngeal carcinoma - Oxford Journals | Medicine ...

epidemiology and aetiology. Nasopharyngeal carcinoma (NPC) is rare with an incidence of 0.5–2 per 100 000 in Europe and the USA . In Southern China, NPC ...
Read more

Nasopharyngeal Cancer (NPC) - ::The Hong Kong Anti-Cancer ...

Nasopharyngeal Cancer Nasopharyngeal Cancer (NPC) Nasopharyngeal carcinoma (NPC) is the 7th commonest cancer in Hong Kong: 926 new cases were detected in 2008.
Read more

Centre for Health Protection - Nasopharyngeal Cancer

Mortality. NPC caused 312 deaths in 2013, accounting for 2.3% of all cancer deaths. It was the tenth fatal cancer in Hong Kong. The crude death rates of ...
Read more

Nasopharynx cancer - Wikipedia, the free encyclopedia

Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the nasopharynx, the uppermost region of the pharynx ("throat ...
Read more

Nasopharyngeal cancer: ESMO Clinical Recommendations for ...

... Hong Kong Cancer Institute, Prince of Wales Hospital, ... NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. ...
Read more

Hong Kong Nasopharyngeal Cancer Symposium 2014 » Cheung ...

Hong Kong Nasopharyngeal Cancer Symposium 2014 Cheung Kung Hai Lecture Theatre, Li Ka Shing Faculty of Medicine, 21 Sassoon Road, Pokfulam, Hong Kong 23-24 ...
Read more

Nasopharyngeal Cancer Symptoms, Causes and Treatment on HKCF

Information about Nasopharyngeal Cancer causes, symptoms, and treatment to Nasopharyngeal Cancer from Hong Kong Cancer Fund.
Read more